Drug Discovery Process: High Throughput Screening Explained | UCSF

Added:

Phenotypic Drug Discovery and Rational Design

While High-Throughput Screening (HTS) is a cornerstone of modern pharmaceutical development, critics argue that its reductionist, target-centric approach often yields high false-positive rates and fails to translate into clinical success. Two major alternative paradigms challenge the dominance of physical HTS: Phenotypic Drug Discovery (PDD) and Rational (In Silico) Drug Design. PDD screens compounds in complex biological systems, such as whole cells or disease models, to observe actual physiological effects. By bypassing the need to define a single molecular target beforehand, PDD accounts for biological complexity and has historically yielded more first-in-class drugs. Conversely, Rational Drug Design and computational (in silico) screening leverage structural biology, machine learning, and molecular modeling to design molecules tailored to a target's 3D structure. This precise, hypothesis-driven method serves as a highly efficient alternative to the brute-force, resource-intensive physical screening of millions of compounds.

Basic principles of biochemistry, particularly protein structure and function, as drug targets are typically proteins such as enzymes or receptors.
The concept of ligand-receptor binding and fundamental pharmacology, including agonist/antagonist interactions and binding affinity.
Familiarity with standard biological assay techniques (e.g., fluorescence, luminescence, and ELISA) used to measure molecular activity.
An introductory understanding of what a chemical library is, representing a vast collection of diverse small molecules used for testing.
Hit-to-lead optimization and medicinal chemistry strategies used to refine the chemical structure of identified 'hits' for better potency and selectivity.
ADME-Tox profiling (Absorption, Distribution, Metabolism, Excretion, and Toxicity) to evaluate the safety and physiological behavior of lead compounds.
Structure-Based Drug Design (SBDD) and computer-aided drug design (CADD) techniques to computationally model target-ligand interactions.
The preclinical and clinical development phases, detailing how a validated lead compound progresses through animal testing and human trials for regulatory approval.
75.9K views832likes44:18@scicommlabOriginal Release: 2010-03-29

The modern drug discovery process involves identifying molecular targets linked to disease, then using high-throughput screening of compound libraries to find initial hits that bind to these targets, followed by iterative optimization to develop clinically viable drugs; this systematic approach evolved from historical methods like natural product screening to contemporary techniques involving biochemical and cell-based assays, with successful compounds needing to meet specific pharmacological criteria including high binding affinity, appropriate molecular weight, and good oral bioavailability.